Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, July 15, 2026, 1:00-2:00 PM ET
Hear an expert discuss how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.
Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine Department of Pathology, SOM at Johns Hopkins University
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
April 2026—Pathologists are physicians who play a crucial role in patient care, providing accurate diagnoses and guiding treatment decisions. Despite often working behind the scenes, pathologists are essential to modern medicine, contributing to advancements in precision medicine and molecular diagnostics.
March 2026—Blood-based biomarkers for Alzheimer’s disease, including the FDA-approved Lumipulse G pTau 217/β-Amyloid 1-42 and Elecsys pTau181 tests, are revolutionizing diagnosis and treatment. These less invasive tests offer earlier detection, improved accessibility, and potential for broader patient reach.
March 2026—An international panel of experts recommended including the determination of intrathecal kappa free light chain (κ-FLC) synthesis in the next revision of MS diagnostic criteria. The κ-FLC index, easily determined by nephelometry and turbidimetry, is a fast, cost-effective, and quantitative biomarker with high diagnostic value for MS. It also predicts future inflammatory disease activity and disability progression, making it a valuable prognostic tool.
March 2026—The Centers for Medicare and Medicaid Services announced changes to personnel requirements in response to feedback on the CLIA final rule.
March 2026—Newer sepsis diagnostics, including monocyte distribution width, Intellisep, and MeMed BV, show promise in clinical studies but have limitations.
March 2026—Laboratory leaders from various health systems discussed strategies to navigate competition and ensure growth.
March 2026—A University of Washington study analyzed HCV testing costs across its system from 2017 to 2024, focusing on the public county hospital ED where one-third of diagnoses occur.
March 2026—Rapid advances in genomic sequencing are reshaping microbial classification and nomenclature, creating challenges for clinical microbiology laboratories.
March 2026—A roundtable discussion focused on improving workflow efficiency in urinalysis, highlighting the potential of AI to enhance reflex testing by integrating test results with EHR data.
March 2026—International medical graduates are crucial to the American healthcare system, particularly in pathology, where they make up a significant portion of the workforce.
